Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's (NOVOb.CO) Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear.
The government's announcement on the 40-million-pound ($50 million) pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the National Health Service's (NHS) specialist weight management scheme.
-230607092956082.jpg)
